Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Kevin Kalinsky, Ingrid A. Mayer et al.|New England Journal of Medicine|2019Cited by 846
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Jordan Berlin et al.|Annals of Oncology|2021Cited by 371
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerEmanuele Perrone, Alessandro D. Santin|Frontiers in Oncology|2020Cited by 60
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecanBurak Zeybek, Alessandro D. Santin|Scientific Reports|2020Cited by 60
Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factorEmiliano Cocco, Alessandro D. Santin|BMC Cancer|2011Cited by 47